Background: Several novel compounds are being developed for inflammatory bowel
| INTRODUCTION
Inflammatory bowel diseases (IBD) comprise two chronic, disabling conditions: Crohn's disease (CD) and ulcerative colitis (UC). 1, 2 In the last two decades, biologic therapies with tumour necrosis factor a antagonists (anti-TNF) have greatly improved care of patients with moderate-to-severe IBD. Four anti-TNF agents have been approved for the treatment of IBD: infliximab, 3, 4 adalimumab, 5, 6 certolizumab pegol, 7 and golimumab. 8 In addition, two anti-integrin agents are available: natalizumab for CD, 9 and vedolizumab for both CD and UC; 10, 11 and recently the interleukin (IL)-12 and IL-23 inhibitor ustekinumab has been approved for the treatment of CD. 12 With an increasing knowledge of the pathogenesis of these immunologically mediated diseases, several novel compounds with different mechanisms of action are being developed and subsequently tested in clinical trials; 13, 14 and many others will enter the pipeline in the future. 15 Their results are eagerly awaited to fill the gaps in IBD care.
It is expected that many new drugs will show positive results, reaching a statistical significant difference against placebo that is required to obtain regulatory approval. However, the magnitude of the difference between groups (ie absolute risk reduction), in terms of efficacy and safety that are clinically relevant in daily practice is a subject of debate, as is the acceptable cost required to achieve those differences. In addition, head-to-head and noninferiority trials become more relevant when the range of our therapeutic armamentarium is increasing. 16 There 2 | ME TH ODS
| Survey design
The first version of the survey was designed by PO and LPB, and reviewed by the members of the IOIBD Clinical Trials Task Force.
After two rounds of modifications, the final version of the survey was approved by consensus. The questionnaire was placed in an online platform (Google Forms, www.google.com/forms, Mountain View, CA, USA), which was only accessible by invitation.
The questionnaire aimed to assess the physicians' perspective on clinical relevance of effect size of therapeutic interventions on various outcomes commonly used in IBD trials. Table S1 .
| Participants
An invitation to participate in this survey was sent via email to all IOIBD members. A reminder was sent 2 weeks after the first invitation. In total, 88 IBD experts were invited to take the survey. All IOIBD members are adult or paediatric gastroenterologists, surgeons, or pathologists who are specialised in IBD, most of whom lead the IBD centres in their respective institutions. Participants completed the survey anonymously.
| Statistical analysis
The results of the survey were analysed using descriptive statistics.
Data are presented as mean AE standard deviation (SD) or N (percentage, %).
3 | RESULTS
| Characteristics of participants
All 88 of the IOIBD members were invited to participate, of whom 46 members (52.3%) replied to the online questionnaire. Details of characteristics of participants are shown in Table 1 , including country of residence, specialty, specialised in adult or paediatric IBD care, years of clinical experience, and number of IBD patients seen per year in their respective centres. There were no differences in answers regarding country of residence. Participants were highly experienced in the field of IBD, with most of them reporting that they had more than 20 years of experience (73.9%), and that they worked at high volume centres (mean 1880 patients/year, SD 1321).
A majority of the participants were gastroenterologist (89%) and were specialised in adult IBD (89%). Figure S1 ). Figure S1 ).
| Head-to-head trials
In head-to-head trials that compare the efficacy of two biologic drugs in Figure S2 ).
When considered biologic-experienced (refractory or intolerant)
patients with moderate-to-severe UC; most of the participants chose as the minimal difference for superiority between groups that would be considered clinically relevant (ie to change clinical practice) 10% and 15% in clinical response (37% and 37% of the answers, respectively), 10% and 15% in clinical remission (52.2% and 19.6% of the answers, respectively), 10% and 15% in endoscopic response (47.8% and 37% of the answers, respectively) and 5% and 10% in endoscopic remission (19.6% and 52.2% of the answers, respectively) ( Table 2 , Figure S2 ).
| Perspective on clinical relevance of CD trials' results

| Placebo-controlled trials
In clinical trials that evaluate the efficacy of new therapeutic interventions against placebo in biologic-na€ ıve patients with moderate-to- Figure S3 ).
| Head-to-head trials
In head-to-head trials that compare the efficacy of two biologic drugs in biologic-na€ ıve patients with moderate-to-severe CD; most of the participants answered that the minimal difference for superiority between groups that they would consider to be clinically relevant (ie to change clinical practice) would be 10% Figure S4 ).
| Bioequivalence studies comparing an originator vs its biosimilar
In bioequivalence studies that compare a biosimilar vs its originator biologic in IBD, most of the participants answered that a clinically important difference between groups would be AE 5% and AE 10% (45.7% and 28.3% of the answers, respectively) in pharmacokinetic parameters, AE 5% and AE 10% (41.3% and 26.1% of the answers, respectively) in clinical efficacy, AE 2.5% and AE 5% (39.1% and 45.7% of the answers, respectively) in safety profile, and AE 2.5%
and AE 5% (39.1% and 43.5% of the answers, respectively) in immunogenicity ( Figure 1 ).
| Non-inferiority trials comparing two different drugs
In non-inferiority trials that compare clinical efficacy and safety of two different drugs in biologic-na€ ıve patients with moderateto-severe UC or CD; most of the participants answered that the adequate non-inferiority margin between groups would be 5% and 10%
(34.8% and 52.2% of the answers, respectively) ( Figure 2 ).
When considered biologic-experienced (refractory or intolerant)
patients with moderate-to-severe UC or CD; most of the participants answered that the adequate non-inferiority margin between 
| Cost
For a new drug that has demonstrated similar efficacy and safety with the standard-of-care drug; most of the participants answered that the minimal difference in terms of costs between the drugs necessary to change your clinical practice would be 10% and 15% (30.4% and 28.3% of the answers, respectively) ( Figure 4 ). For drugs with a similar efficacy profile, other factors like treatment costs and safety might drive physicians to choose a particular drug.
| DISCUSSION
We performed a survey to members of the IOIBD to clarify physicians' perspective in this matter. To the best of our knowledge, this is the first time that an initiative is made to define how physicians apperceive IBD clinical trials' results.
Participants who took the survey were highly experienced and from different regions of the world ( More than half of respondents considered 10% to be an adequate margin in non-inferiority trials. In bioequivalence studies, most of the participants considered adequate a AE 5% difference between a biosimilar and the originator for pharmacokinetic parameters, efficacy, safety and immunogenicity. Although there are no such studies in IBD population yet, the results of equivalence studies of biosimilar infliximab for other immune-mediated diseases, have led to their approval in IBD by extrapolation. 22 In rheumatoid arthritis patients, two phase 3 equivalence studies compared the efficacy and safety of originator infliximab vs biosimilar CT-P13 and SB2 respectively. 23, 24 They both used an equivalence margin of AE 15%. According to the World Health Organization guidance, "equivalence/noninferiority margins have to be pre-specified and justified based on clinical relevance; that is, the selected margin should represent the largest difference in efficacy that would not matter in clinical practice." 25 An interesting observation from the results is that there is a disconnect between what physicians consider adequate, what is feasible to demonstrate from the statistical point of view. This dissociation depends on the type of study, the variable of interest and most importantly the magnitude of the difference between groups considered being adequate. Figure 5 shows the sample sizes needed to demonstrate these differences, according to the study type and the statistical power considered. In superiority trials, both in placebo-controlled and head-to-head, most of the participants considered adequate a 15% or 10% difference for most | 779 of the endpoints. Considering a statistical power of 80%, the number of subjects needed per group would be 173 and 388 respectively, which seems reasonable and similar to those of current phase 3 trials. On the other hand, in bioequivalence studies a 5% equivalence limit was considered adequate by most of participants for all variables, pushing the number of subjects needed per group up to 822, which is clearly very difficult to fulfill and if implemented would limit access to biosimilars. In non-inferiority trials, most of the participants considered adequate a 10% and 5% margin; this would mean that the number of subjects per group to demonstrate such a margin (considering a statistical power of 80%) would be 281 and 1159 respectively. Clearly, this slight difference between the margins has enormous implications in a study practicability.
Regarding safety, the difference between two drugs considered clinically relevant varied from 0.5% to 5%, depending on the type of adverse event. Most of participants considered a 0.5% to 1% difference in serious adverse events considerable enough to change their clinical practice. It is evident that such a difference is impractical to demonstrate in clinical trials. Once again, the sample size needed to demonstrate such as difference is almost impossible to recruit considering the incidence and prevalence of IBD. What is more, such adverse events usually take years or even decades to occur (eg malignancy), beyond the time period of most clinical trials. For these reasons, it is probable that we will still have to rely in large, post-marketing registries, such as the I-CARE (NCT02377258), to evaluate the incidence of rare (and potentially serious) adverse events. The main strength of this study was to evaluate and quantify for the first time a subject much debated between peers. Different variables were evaluated, as well as different study designs that will be more common in the future (ie head-to-head, non-inferiority and bioequivalence studies). This study has some limitations. Firstly, the sample size was relatively small; a 52% participation rate can be explained by the fact that the invitation to take the survey was sent to all IOIBD members, including active and also senior members, which might have turned the participation rate down. 
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